Analyst: Gilead should buy Vertex; Biocon eyes an IPO for Syngene unit;

@FierceBiotech: Salk heavyweight Evans raising $33M for an intriguing stealth biotech. Report | Follow @FierceBiotech

@JohnCFierce: Re-patients. I'm not buying the "you're a cynic" response. Manipulating patients for commercial gain and PR cover is SOP in biopharma. | Follow @JohnCFierce

> Gilead Sciences ($GILD) should spend its growing pile of cash on Vertex Pharmaceuticals ($VRX), according to Bernstein analyst Geoff Porges, arguing the latter company is worth $45 billion. Item

> Indian drugmaker Biocon is planning an IPO for its CRO business. More

> The recent hot streak in biotech venture capital has resulted in some eye-popping rounds, but the number of companies funded has stayed largely flat. Story

Medical Device News

@FierceMedDev: WuXi and DNAnexus join up for cloud-based genomic services. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Study finds Boston Scientific's S-ICD has sterling safety profile, quarterly sales exceed $100M. Report | Follow @VarunSaxena2

@EmilyWFierce: FBI admits to decades of flawed hair analysis. Washington Post story | Follow @EmilyWFierce

> Google-backed telemedicine company raises $15M to support its Spruce app. Item

> Medtronic touts the first neurostimulator to get approval for use during full-body MRI scan. Report

Pharma News

@FiercePharma: Think the pharma M&A party will start winding down? Think again. Item | Follow @FiercePharma

@EricPFierce: Chinese API maker Yunnan Hande Bio-Tech gets a second FDA warning letter. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Perrigo spurned Mylan's $29B offer, but would a bigger one do? Story | Follow @CarlyHFierce

> RB recalls 1.5M units of Mucinex on acetaminophen concerns. Item

> Teva wants Mylan wants Perrigo, and the pundits go mad with opinions. More

> Gilead should buy Vertex, analyst suggests--and the time is now. Article

Biotech Research News

> AbbVie, Infinity tout preclinical evidence of a cancer combo's potential. Story

> MD Anderson takes experimental lung cancer drug into the clinic. Report

> Seeking a drug cocktail, CSHL team points to a new pathway for breast cancer. More

> Yale cancer group refines an antibody approach to targeting cancer cells. Story

> Small European study highlights promise of gene therapy for rare immune disease. Article

Diagnostics News

> LabCorp rides direct-to-consumer wave with online testing services. More

> Quest joins forces with French health agency for BRCA research initiative. Report

> Cardinal Health pays feds $26M to settle charges of monopolizing molecular imaging agent market. Story

> Color Genomics unveils $249 spit test for breast and ovarian cancer. Item

> Focus Diagnostics gets FDA nod for rapid strep test. Article

Pharma Marketing News

> Attention pharma laggards: FitBit trackers delivered in Biogen's MS movement study. News

> How to make sure DTC doesn't turn off patients? Ask them to tailor your ads. Article

> Pharma's getting savvier about social, with Boehringer, Bayer leading the pack. More

> Pfizer's Lyrica team matches the spokesman to the message. Story

> Merck aims for double payoff with new diabetes education push. Article

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.